DORAL, Florida, Dec. 31, 2018 (GLOBE NEWSWIRE) --
Earth Science Tech, Inc. (ETST) (âETST" or
the âCompany"), an innovative biotech company focused on the
cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical
devices, and research and development, reviews the Companyâs 2018
achievements and shares whatâs to come in 2019.
During the fiscal first quarter, the
Company expanded its
executive team with the appointment of Jill Buzan as a new Chief
Sales Officer (CSO) and Wendell Hecker as Chief Financial Officer
(CFO). Since the first of the year, under Buzan and
Heckerâs leadership, sales have increased over 100 percent. The
Company has also become fully reporting, employing accurate
bookkeeping throughout the process.
At the end of Q1, the Company appointed a new
chief operating officer (COO), while Nickolas S.
Tabraue, the COO at the time, continued as President, Director and
Chairman to focus on the companyâs expansion. Since the addition of
Gagan Hunter as COO, the Company has increased inventory control
accuracy, which has assisted in the full reporting process and made
company audits easier, ultimately helping the company achieve a
smooth transition as it grows.
During the fiscal second quarter, the
Company added a pharmacist
& LP3 as Chief of Pharmacy, furthering efforts to
obtain a license to distribute controlled substances. Since Jad
Nammour joined the Company, he has assisted in the development of
the Companyâs CBD nutraceutical-based IPs and medical device.
During the fiscal third quarter, the
Company achieved fully
reporting status with the SEC under the exchange act of
1934. Since achieving fully reporting status and with
the resulting increased transparency, the Company has been able to
obtain more direct and retail investors.
In the middle of Q3, the Company officially uplisted
to the OTCQB Exchange, operating as a OTCQB Company
with fully reporting status. This status has positioned the Company
to a higher standard, providing a strong baseline for transparency
as well as technology and regulations that improve the flow of
information and trading experience for investors. U.S. investors
can find current financial disclosure and real-time level2 quotes
At the end of Q3, the Company initiated a DRTV media
campaign with former Shark Tank star Kevin Harringtonâs
award-winning As Seen On TV production company.
Production on the campaign has begun and the Company anticipates a
Q2019 launch date. The campaign being created for ETST will
Â·A 60-second DRTV commercial spot to be aired 300
times within 10 selected regions and selected networks.
Â·A 15-second promotional video to be used for
digital and social media purposes.
Â·A featured placement on the website for 13
Â·Complete licensing rights to the commercial spot
and promotional video, and permission to use the world famous As
Seen On TV logo on ETSTâs products.
During the fiscal fourth quarter, the Companyâs
partnership with Bionatus is almost market ready.
A major Q4 achievement was the Companyâs first commercial
production run of Hygee(TM) medical device kits that
easily test for chlamydia. Hygeeâ¢ anticipates strong sales growth
in years two and three after product launch. As soon as year one,
sales of Hygeeâ¢ and the associated in vitro molecular
diagnoses should reach between $1.5 million and $2.5 million USD.
Second year sales should reach $1 million monthly and up to $20
million yearly as early as the third year. These numbers are
supported by the fact that chlamydia is a global issue; that the
companyâs network of distributors is worldwide; and that the thin
structure of the device and the stability of the specimen collected
with Hygeeâ¢ ensures that it can be easily dispersed on all
At the end of Q4, the Company engaged counsel
with Canadian Securities Exchange (CSE) expertise to assist with
dual listing. Listing could happen as early as in the
third quarter of the Companyâs current fiscal year and would
require certain regulatory approvals that would allow Earth Science
to market and sell its common shares to Canadian investors.
ETST Management Reviews 2018,
âIn 2018, we made sufficient changes to i
mprove our point of sale system, inventory and accounting
management systems, improved on our manufacturing and packaging,
strengthened the potency and effectiveness of our products, and
increased our sales I am confident with the implementation of
these changes and the addition of our new CSO, David Barbash. The
company will reach new heights in 2019 as we now focus on
increasing and expanding our sales force and employ a new marketing
team. As we increase our distribution and presence in the
marketplace, 2019 will be the best year in the company's history.â
- Gagan Hunter, COO & Director
âI am very proud of all the work
of our team and partners in 2018. Together we have
created a culture of creativity and an enormous potential
of growth. With the launch of our new product lines and
our ongoing program of research and development, I anticipate an
incredible 2019 for the company. I am devoted to our
shareholders interests, and to helping everyone on the planet who
aspires to a better life through better health. I wish you all the
very best for the year to come, and that you share the same
kind of success as Earth Science Tech.â - Dr. Michel AubÃ©, CEO
& Chief Science Officer
âThere is a solid foundation to build on in
2019 here at ETST and with major distribution expansion planned in
the New Year on the heels of the signing of the Farm Bill, I
see a great reason to be enthused about actualizing the potential
here.â â David Barbash,The Companyâs new Chief Sales
âIn 2018 the Company became fully
reporting, uplisted, improved our High Grade Full Spectrum line,
increased sales over 100%, ordered our first batch of Hygee(TM) to
launch early 2019, and engaged council to assist in the Canadian
dual exchange. We are positioned to catapult during 2019. We have a
solid executive team, company transparency, and everything is set.
I truly look forward to the new year exceeding everyoneâs
expectations in company growth and revenue.â - Nickolas S. Tabraue,
President, Director and Chairman
About Earth Science Tech, Inc.
Earth Science Tech, Inc. (âETSTâ) offers the highest purity and
quality high-grade full spectrum cannabinoid oil on the market.
There are positive results in studies on breast cancer and immune
cells through the University of Central Oklahoma, in addition to
studies through DV Biologics that prove the Companyâs CBD oil
formulation lowers cortisol and functions as a neuro-protectant,
with positive result case studies through key health organizations.
ETST formulates, markets and distributes the CBD oil used for its
studies to the public, offering the most effective quality of CBD
on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries
focused on developing its role as a world leader in the CBD space
and expanding its work in the pharmaceutical and medical device
Earth Science Pharmaceutical,
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary
of Earth Science Tech, committed to the development of low cost,
non-invasive diagnostic tools, medical devices, testing processes
and vaccines for sexually transmitted infections and/or diseases.
ESP's CEO and chief science officer, Dr. Michel AubÃ©, is
leading the Companyâs research and development efforts. The
Companyâs first medical device, Hygeeâ¢, is a home kit designed for
the detection of STIs, such as chlamydia, from a self-obtained
gynecological specimen. ESP is working to develop and bring to
market medical devices and vaccines that meet the specific needs of
women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics (âCTIâ) is a wholly-owned subsidiary of Earth
Science Tech, Inc. poised to take a leadership role in the
development of new, leading-edge cannabinoid-based pharmaceutical
and nutraceutical products. CTI is invested in research and
development to explore and harness the medicinal power of
cannabidiol. The company holds three provisional application
patents for a CBD product that is focused on developing treatments
for breast and ovarian cancers, as well as two generic CBD based
pharmaceutical drugs. To learn more please visit: www.CannabisThera.com